logo-loader

Futura Medical’s CEO discusses £12m fundraising for MED3000

Published: 14:18 17 May 2021 BST

Futura Medical PLC's (LON:FUM) James Barder talks to Proactive London's Katie Pilbeam to explain the plans for their £12mln fundraise. 

Firstly, manufacturing scale up, the firm needs to commit to certain capex to fully automate production. They have also retained corporate advisers and are expecting to announce further distribution agreements during the remainder of 2021 in addition to the Asia agreement they announced in early March. 

Also following the clear guidance from the FDA regarding the protocol they have been able to accurately cost the study at £3 million. 

And finally to strengthen balance sheet and fund all required activities for the company through until at least US MED3000 launch.

Futura Medical marks pivotal year with first meaningful revenue from Eroxon...

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes...

on 7/2/24